Furthermore, to our knowledge, this is the first publication of evidence that SRD5A3 has at least one nARE and that AR directly binds to this nARE region, demonstrating that SRD5A3 is under transcription inhibition by AR in prostate cancer cells. The gene discussed is AR; the disease is prostate cancer.